# US 2019/0241642 A1 · System and method for homogenous gpcr phosphorylation and identification of beta-2 adrenergic receptor positive allosteric modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0241642 A1
- Document ID: US20190241642A1
- Status: Published application
- Kind: A1
- Application number: 16/269,877
- Filed: 2019-02-07
- Published: 2019-08-08
- Earliest claimed: 2018-02-07
- Assignees: Duke University
- Applicants: Duke University
- Inventors: Robert J. Lefkowitz; Seungkirl Ahn; Biswaranjan Pani; Alem W. Kahsai; Laura Wingler; Dean Staus
- Web page: https://patentgrep.com/patent/US20190241642A1

## CPC

- C07K 14/723: {G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor}
- C07K 14/4703: {Inhibitors; Suppressors}
- C07K 14/70567: {Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}
- C07K 14/70571: {for neuromediators, e.g. serotonin receptor, dopamine receptor}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/43: containing a FLAG-tag
- C07K 2319/70: containing domain for protein-protein interaction
- G01N 2333/726: G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/10: involving cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The disclosure is directed to a G-protein coupled receptor complex. The complex includes (i) a chimeric G protein-coupled receptor (GPCR) comprising a non-native amino acid sequence located within the C-terminus of the GPCR and a synthetic phosphopeptide ligated to the non-native amino acid sequence; and (ii) a β-arrestin (βarr) protein bound to the C-terminus of the GPCR. The disclosure also provides an in vitro method for producing the aforementioned complex, as well as methods for identifying compounds or ligands which bind to and modulate the activity of the complex. Positive allosteric modulators of the β2 adrenergic receptor identified by screening a DNA-encoded library potentiate the activity of β2 agonists and have application in the treatment of obstructive airway disease, bronchospasm, or pre-term labor.

## Claims

### Claim 1

A complex comprising:
(i) a chimeric G protein-coupled receptor (GPCR) comprising the amino acid sequence LPETGGG (SEQ ID NO: 1) located within the C-terminus of the GPCR and a synthetic phosphopeptide ligated to SEQ ID NO: 1; and
(ii) a β-arrestin (βarr) protein bound to the C-terminus of the GPCR.

### Claim 2 (depends on 1)

The complex of claim 1, which further comprises an antigen-binding fragment of an antibody (Fab) that specifically binds to the complex.

### Claim 3 (depends on 1)

The complex of claim 1, wherein the chimeric GPCR is a member of the adrenergic receptor family, a member of the dopamine receptor family, a member of the opioid receptor family, a member of the muscarinic acetylcholine receptor family, calcitonin receptor (CTR), a cannabinoid receptor, a chemokine receptor, a free fatty acid receptor, G protein-coupled receptor 3, glucagon-like peptide 1 receptor (GLP-1R), a parathyroid hormone receptor, a somatostatin receptor, a sphingosine-1 phosphate receptor, a vasopressin receptor, an angiotensin receptor, or thyroid stimulating hormone receptor (TSHR).

### Claim 4 (depends on 3)

The complex of claim 3, wherein the chimeric GPCR is a β2-adrenergic receptor, angiotensin II type 1A receptor, vasopressin V2 receptor, μ opioid receptor (MOR), or muscarinic acetylcholine receptor 2 (M2R).

### Claim 5 (depends on 1)

The complex of claim 1, wherein the synthetic phosphopeptide is derived from the C-terminus of a vasopressin-2-receptor (V2R).

### Claim 6 (depends on 5)

The complex of claim 5, wherein the synthetic phosphopeptide comprises the amino acid sequence ARGRTPPSLGPQDESCTTASSSLAKDTSS (SEQ ID NO: 2).

### Claim 7 (depends on 6)

The complex of claim 6, wherein the synthetic phosphopeptide is phosphorylated at residues 5, 8, 15, 17, 18, 20, 21, and 22 of SEQ ID NO: 2.

### Claim 8 (depends on 1)

An in vitro method for producing the complex of claim 1, which method comprises:
(a) enzymatically ligating a synthetic phosphopeptide to the C-terminus of a purified GPCR to produce a phosphorylated chimeric GPCR comprising the amino acid sequence of SEQ ID NO: 1 located within the C-terminus of the GPCR, and
(b) contacting the phosphorylated chimeric GPCR with purified β-arrestin (βarr) protein, whereupon the purified β-arrestin (βarr) protein binds to the C-terminus of the phosphorylated chimeric GPCR and forms a complex comprising the chimeric GPCR and the βarr protein.

### Claim 9 (depends on 8)

The method of claim 8, wherein the purified GPCR comprises the amino acid sequence LPETGGH (SEQ ID NO: 3).

### Claim 10 (depends on 8)

The method of claim 8, wherein the ligation is catalyzed by a sortase enzyme.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A method for selecting a modulator of a G protein-coupled receptor (GPCR), which method comprises (i) contacting the complex of claim 1 with one or more compounds under conditions to allow for measurement of an activity of the one or more compounds at the chimeric GPCR, (ii) measuring the presence or absence of activity of the one or more compounds, and (iii) selecting at least one compound that displays the activity at the chimeric GPCR.

### Claim 13 (depends on 12)

The method of claim 12, further comprising
measuring a reference activity at (a) an equivalent chimeric GPCR without C-terminal phosphorylation, (b) an equivalent chimeric GPCR in the absence of β-arrestin, (c) an equivalent chimeric GPCR in the presence of G protein, and/or (d) an equivalent GPCR with a native C-terminus, for the at least one compound that displays activity at the chimeric GPCR; and
selecting a compound that exhibits a difference in the activity at the chimeric GPCR compared to the reference activity.

### Claim 14 (depends on 13)

The method of claim 13, wherein the difference in the activity is an enhancement in the activity at the chimeric GPCR compared to the reference activity.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 13)

The method of claim 13, wherein the difference in the activity is a decrease in the activity at the chimeric GPCR compared to the reference activity.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 12)

The method of claim 12, further comprising
measuring a reference activity at (a) an equivalent chimeric GPCR without C-terminal phosphorylation, (b) an equivalent chimeric GPCR in the absence of β-arrestin, (c) an equivalent chimeric GPCR in the presence of G protein, and/or (d) an equivalent GPCR with a native C-terminus, for the at least one compound that displays activity at the chimeric GPCR; and
selecting a compound that exhibits substantially no difference in the activity at the chimeric GPCR compared to its reference activity.

### Claim 21 (depends on 12)

The method of claim 12, wherein the activity is a binding activity.

### Claim 22 (depends on 12)

The method of claim 12, wherein the activity is a functional activity selected from the group consisting of agonism of the chimeric GPCR, positive allosteric modulation of the chimeric GPCR, neutral antagonism of the chimeric GPCR, inverse agonism of the chimeric GPCR, and negative allosteric modulation of the chimeric GPCR.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 12)

The method of claim 12, which comprises selecting at least one compound that binds to the chimeric GPCR and activates at least one signaling pathway over one or more other signaling pathways mediated by the chimeric GPCR.

### Claim 30 (depends on 29)

The method of claim 29, wherein the compound preferentially activates a βarr-dependent signaling pathway over a G protein-dependent signaling pathway or the compound preferentially activates a G protein-dependent signaling pathway over a βarr-dependent signaling pathway.

### Claim 31 (depends on 30)

The method of claim 30, wherein the βarr-dependent signaling pathway is Mitogen-Activated Protein Kinase (MAPK) signaling, receptor transactivation, receptor trafficking, protein ubiquitination, transcriptional regulation, GPCR desensitization, or GPCR internalization.

### Claim at position 32

32-79. (canceled)
